A Two-part Study To Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera

Trial Profile

A Two-part Study To Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Givinostat (Primary)
  • Indications Polycythaemia vera
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Italfarmaco
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
    • 01 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top